

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:			Currie et al.									
Serial No.:			To Be Assigned	Group Art Unit:								
File Date:			Concurrently Herewith	Examiner:								
For:			Pharmaceutical Compositions Comprising Abacavir and Lamivudine									
P.O.	Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450											
	INFORMATION DISCLOSURE STATEMENT											
Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97												
Ī	[] Copies of the references are enclosed: [] Copies of the references were submitted in parent application											
Α. [A. [X] The Information Disclosure Statement submitted herewith is being filed within three months filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).											
OR [] The Information Disclosure Statement submitted herewith is being filed before the of a first office action after the filing of a Request For Continued Examination un C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).												
В. [[]	filing date o an internation event occurr (1) a fi	f the above application or the date of									
	[]	Statement w		mation contained in this Information Disclosure foreign patent office in a counterpart foreign he filing of this statement.								
	[]		cts the option to pay the fee set forth atement under § 1.97(c) (\$180.00).	in 37 CFR 1.17(p) for submission of an Information								
C. [[]	1.113, or a r	otice of allowance under § 1.311, w lso enclosed is a copy of the Interna	ed herewith is being filed after a final action under § hichever occurs first, but before the payment of the tional Search Report which Issued on International								

In accordance with the requirements of 37 CFR 1.97(d):



- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Karen L. Prus

Registration No. 39,337

Date: Michael 2 404
GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2192 Facsimile: (919) 483-7988

10/516577 DT05 Bee'd PCT/PTO 0 2 DEC 2004

FORM PTO-14	449 ON DISCLOSURE ST	TATEMENT		ATTORNEY DOCKET NO. PU4828USW SERIAL NO. To Be Assigned				
INFORMATIC	JN DISCLOSURE S	ALLMENT		APPLICANT: Cur	rrie et al.			
				FILING DATE: Concurrently Herewith		GROUP		
		U.S. F	PATENT D	OCUMENTS	- 1-			
Examiner Initials	Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate	
							.	
			<u> </u>				 	
		 	-		<u> </u>	 	 	
	- 		_			· · · · · · · · · · · · · · · · · · ·	·	
			ontinue on	Page T DOCUMENTS				
<u> </u>	Document	Publication	HIAILIN	I DOCUMENTS _	T		Translation	
	Number	Date		Country	Class	Subclass	Yes No	
	WO 00/16779	Mar. 30, 2000	WIPO			ļ	ļ	
	WO 96/30025 WO 99/55372	Oct. 3, 1996 Nov. 4, 1999	WIPO			<u> </u>	-	
	WO 99/55372	Nov. 4, 1999	WIPO			 		
		-	 					
							-	
			 					
		C	ontinue on	page		<u>. </u>		
		MENTS (Includi	ng Author,	Title, Journal-Date				
	of Some Powde	rs and Tablets." S	Stp. Pharma	ilicified and Non-Sil Sciences, Paris, Fr.,	Vol. 11, No. 2	, March 2001.		
	International Jou	ırnal of Pharmace	utics (Amst	rocrystalline Cellulo erdam), vol. 182, no.	2, May 25, 19	99		
	Proceedings of the	he Controlled Rel	ease Society	ming Excipients in H y 1998 United States	, No. 25, 1998,	pgs. 948-949.		
	Properties of Soi	me Pharmaceutica	l Compoun	ssion of Tablets. XII ds and Their Mixture anufacture 1985 Uni	es with Avicel	105." Internati	onal Journal	
					•			
<u>_</u>		Č	Continue on	page			-	
EXAMINER				F 3-	DATE CO	ONSIDERED		
	nitial if citation consid	lered, whether or i	not citation	is in conformance wi	th MPEP § 609	9; Draw line th	rough citation	
	nance and not consider							

BEST AVAILABLE COPY